Prostate-specific antigen vaccines for prostate cancer

Expert Opinion on Biological Therapy

Volumn 2, Issue 4, 2002, Pages 395-408

  Hörig, Heidi ^a   Lee, Christopher S D ^a   Kaufman, Howard L ^a  

^a New York Presbyterian Hospital Columbia University Medical Center   (United States)

Author keywords

Immunotherapy; Prostate cancer; Prostate specific antigen (PSA); Tumour markers; Vaccines

Indexed keywords

CANCER VACCINE; CYTOKINE; EPITOPE; IMMUNOMODULATING AGENT; PROSTATE SPECIFIC ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER STAGING; CLINICAL TRIAL; DENDRITIC CELL; DRUG EFFICACY; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; FEASIBILITY STUDY; HLA SYSTEM; HUMAN; MALE; NONHUMAN; PROSTATE CARCINOMA; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE;

ANIMALS; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; MALE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

ANIMALIA;

EID: 0036244549     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2.4.395     Document Type: Review

References (104)

1. Treatment of progressive metastatic prostate cancer
2. The use of prostate specific antigen, clinical stage, and Gleason score to predict pathological stage in men with localized prostate cancer
3. Advances in prostate cancer
4. Generation and genetic characterization of immortal human prostate epithelial cell lines derived from primary cancer specimens
5. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide
6. Different response of lymphoid cells from tumor-bearing as compared to tumor-immunized mice when sensitized to tumor specific antigens in vitro
7. Identification of a novel cell type in peripheral lymphoid organs of mice. IV. Identification and distribution in mouse spleen
8. Cross-presentation, dendritic cells, tolerance and immunity
9. Antigen-pulsed CD8alpha+ dendritic cells generated an immune response after subcutaneous injection without homing to the draining lymph node
10. Granzymes, a family of serine proteases released from granules of cytolytic T lymphocytes upon T cell receptor stimulation
11. A null mutation in the perforin gene impairs cytolytic T lymphocyte- and natural killer cell-mediated cytotoxicity
12. TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties
13. The immunological synapse: A molecular machine controlling T cell activation
14. Natural killer cells in antiviral defense: Function and regulation by innate cytokines
15. Ligands for natural killer cell receptors: Redundancy or specificity
16. CD4 T cells and their role in antitumor immune response
17. The central role of CD4 (+) T cells in the antitumor immune response
18. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
19. CD40 ligand promotes priming of fully potent antitumor CD4 (+) T cells in draining lymph nodes in the presence of apoptotic tumor cells
20. CD4 (+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma
21. CD4+ T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen
22. CD4+ cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cell
23. Execution and suicide: Cytotoxic lymphocytes enforce Draconian laws through separate molecular pathways
24. Fas- and perforin-independent mechanism of cytotoxic T lymphocyte
25. Fas and FasL in the homeostatic regulation of immune responses
26. Antigen processing and presentation by the class I major histocompatibility complex
27. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy
28. TAP (transporter associated with antigen processing)-independent presentation of endogenously synthesized peptides is enhanced by endoplasmic reticulum insertion sequences located at the amino-but not carboxyl-terminus of the peptide
29. Antigen processing in vivo and the elicitation of primary CTL responses
30. Extensive trafficking of MHC class II-invariant chain complexes in the endocytic pathway and appearance of peptide-loaded class II in multiple compartments
31. Lysosome-associated membrane protein-1-mediated targeting of the HIV-1 envelope protein to an endosomal/lysosomal compartment enhances its presentation to MHC class II-restricted T cells
32. Minor H antigens introduced on H-2 different stimulating cells cross-react at the cytotoxic T cell level during in vivo priming
33. Multiple antigen-specific processing pathways for activating naive CD8+ T cells in vivo
34. In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter
35. Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cell: Pathway of presentation and regulation by cytokines
36. Roles of heat-shock proteins in antigen presentation and cross-presentation
37. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations
38. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
39. Immunohistochemical demonstration of prostate-specific antigen in metastases with the use of monoclonal antibody F5
40. Prostate specific antigen: A decade of discovery - What we have learned and where we are going
41. Prostate cancer is highly predictable: A prognostic equation based on all morphological variables in radical prostatectomy specimens
42. Characterization of the prostate-specific antigen gene: A novel human kallikrein-like gene
43. A retrospective and prospective overview of prostate-specific antigen
44. Detection of prostate specific antigen in pancreas and salivary glands: A potential impact on prostate cancer overestimation
45. Re: Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer
46. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen
47. Recognition of prostate-specific antigenic peptide determinants by human CD4 and CD8 T cells
48. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha
49. Generation of CD4 (+) and CD8 (+) T lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigen/antibody) complexes
50. Exogenous antigen targeted to Fc gamma RI on myeloid cells is presented in association with MHC class I
51. Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA
52. Dendritic cells transduced with HSV-1 amplicons expressing prostate-specific antigen generate antitumor immunity in mice
53. Direct gene transfer into mouse muscle in vivo
54. Heterologous protection against influenza by injection of DNA encoding a viral protein
55. Specific immune induction following DNA-based immunization through in vivo transfection and activation of macrophages/antigen-presenting cell
56. Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine
57. Engineering enhancement of immune responses to DNA-based vaccines in a prostate cancer model in rhesus macaques through the use of cytokine gene adjuvants
58. Induction of immune responses and safety profiles in rhesus macaques immunized with a DNA vaccine expressing human prostate specific antigen
59. Recombinant viruses as vaccines and immunological tools
60. A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): Safety and immunogenicity in a non-human primate
61. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer
62. A Phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer
63. Poxvirus-based vectors as vaccine candidates
64. Carbohydrate vaccines in cancer: Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man
65. Immunotherapy of advanced prostate cancer: A Phase I/II trial using Mycobacterium vaccae (RL172)
66. Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer
67. Oil-in-water liposomal emulsions: Characterization and potential use in vaccine delivery
68. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A Phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease
69. Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment
70. Follow-up evaluation of a Phase II prostate cancer vaccine trial
71. GM-CSF as a systemic adjuvant in a Phase II prostate cancer vaccine trial
72. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: A Phase I/II clinical trial
73. Improved immunohistochemical detection of prostatic acid phosphatase by a monoclonal antibody
74. Gene expression and prostate specificity of human prostatic acid phosphatase (PAP): Evaluation by RNA blot analyses
75. Immunohistochemical diagnosis of prostatic cancer with metastasis
76. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: Implications for immunotherapy of prostate cancer
77. Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phospharase peptide
78. Identification of T helper epitopes from prostatic acid phosphatase
79. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells
80. Three predominant proteins secreted by the human prostate gland
81. Route of immunization and the therapeutic impact of recombinant anticancer vaccines
82. Immunological properties of gene vaccines delivered by different routes
83. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity
84. Interleukin 2 gene therapy for prostate cancer: Phase I clinical trial and basic biology
85. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and anti-tumor response
86. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses
87. Growth inhibition of an MC-induced mouse sarcoma by TCGF (IL-2) containing preparations. Preliminary report
88. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastasis
89. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine
90. Immunizing patients with metastatic melanoma using recombinant adenoviruses encodingMART-1 or gp100 melanoma antigens
91. Bronte Vetal.: IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines
92. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma
93. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression
94. Vaccination with irradiated tumor cells engineered to secrete murine granulocytemacrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
95. Enhancement of antitumor immunity by CTLA-4 blockade
96. CD28 and CTLA-4 have opposing effects of the response of T cells to stimulation
97. T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles
98. Construction and characterization of a recombinant vaccinia virus expressing murine intercellular adhesion molecule-1: Induction and potentiation of antitumor responses
99. Induction of anti-tumor immunity elicited by tumor cells expressing a murine LFA-3 analog via a recombinant vaccinia virus
100. Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity
101. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules
102. A triad of costim ulatory molecules synergize to amplify T-cell activation
103. Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules
104. Tumor antigens recognized by T cells